Japan Tobacco (2914) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
25 Aug, 2026Executive summary
Revenue and adjusted operating profit (AOP) increased significantly in H1 2026, with revenue up 17.7% to ¥1,986.1 billion and AOP at constant FX up 19.4% year-on-year, driven by strong tobacco and processed food businesses.
Operating profit rose 29% year-on-year to ¥644.9 billion, and net profit increased 28.9% to ¥431.8 billion, supported by lower financial costs and reduced amortization of intangible assets.
Results exceeded initial forecasts, fueled by robust pricing, positive FX impacts, and strong performance in key markets.
The pharmaceutical business was classified as discontinued operations following its transfer and sale in 2025; all figures reflect continuing operations.
Annual dividend guidance raised by JPY 30 to JPY 272, based on improved profit outlook and shareholder return policy.
Financial highlights
Consolidated revenue for Jan–Jun 2026 rose 17.7% year-over-year to JPY 1,986.1 billion; core revenue at constant FX in tobacco rose 10.6% year-on-year, with price mix contributing 10.2%.
Adjusted operating profit (AOP) increased 26.2% to JPY 661.7 billion; at constant FX, AOP grew 19.4%.
RRP (reduced-risk products) volume surged 33.8% year-on-year, led by Ploom's 43.5% growth; RRP-related revenue up 40.7%.
Processed food revenue increased by JPY 2.5 billion year-on-year to JPY 79.2 billion, mainly from price revisions in packed cooked rice.
Free cash flow revised upward by JPY 121 billion, mainly due to higher AOP.
Outlook and guidance
Full-year 2026 revenue forecast revised upward by JPY 188.0 billion to JPY 3,885.0 billion (+12.0% vs. 2025); core revenue at constant FX revised up by JPY 80 billion, now expected to grow 6% year-on-year.
AOP at constant FX revised up by JPY 24 billion, now expected to increase 11.6% year-on-year; AOP forecast raised by JPY 80.0 billion to JPY 1,035.0 billion (+16.9% vs. 2025).
Net profit forecast increased by JPY 74.0 billion to JPY 644.0 billion (+29.0% vs. 2025).
Dividend guidance raised by JPY 30 to JPY 272, with a payout ratio of 75.2% after Canada adjustment.
H2 expected to see softer volume and moderated growth due to tax-driven price increases and higher supply chain costs.
Latest events from Japan Tobacco
- Q1 2026 delivered strong revenue and profit growth, with robust outlook and high dividend forecast.2914
Q1 2026 - Record-high profit and revenue in FY2025, with robust outlook and continued RRP expansion.2914
Q4 2025 - Record-high profit and revenue, higher guidance, and increased dividend after business divestiture.2914
Q3 2025 - Strong revenue and profit growth led to higher forecasts and dividend guidance for 2025.2914
Q2 2025 - Strong tobacco pricing and RRP growth drove higher profit and raised full-year guidance.2914
Q2 2024 - Revenue up 11% and US market share expanded via Vector, but profit faces cost and litigation risks.2914
Q3 2024 - Q1 2025 saw robust profit growth, pharma divestment to Shionogi, and steady dividend guidance.2914
Q1 2025 - Record revenue and profit growth in FY2024, with high single-digit AOP growth targeted for 2025.2914
Q4 2024